Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
240
ADARx Clinical Site
Gilbert, Arizona, United States
RECRUITINGADARx Clinical Site
Evaluate the effect of ADX-038 on the preservation of the EZ layer
Rate of change in the area of total EZ loss in the study eye from baseline to Month 12
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Phoenix, Arizona, United States
ADARx Clinical Site
Beverly Hills, California, United States
RECRUITINGADARx Clinical Site
Huntington Beach, California, United States
NOT_YET_RECRUITINGADARx Clinical Site
Poway, California, United States
NOT_YET_RECRUITINGADARx Clinical Site
Orlando, Florida, United States
ENROLLING_BY_INVITATIONADARx Clinical Site
Hagerstown, Maryland, United States
RECRUITINGADARx Clinical Site
Erie, Pennsylvania, United States
RECRUITINGADARx Clinical Site
McAllen, Texas, United States
RECRUITINGADARx Clinical Site
Round Rock, Texas, United States
RECRUITING...and 7 more locations